AR and prostate carcinoma: To verify ASPN-induced HER2 pathway activation in human prostate cancer cells, androgen-responsive (LNCaP and VCaP), androgen receptor (AR) inhibitor–resistant (enzalutamide) (LNCaPenzaR and VCaPenzaR), and androgen-insensitive (PC3, DU145) prostate cancer cells were treated with recombinant human ASPN and assessed by immunoblotting.